The introduction of new vaccines into developing countries. V: Will we lose a decade or more in the introduction of dengue vaccines to developing countriesα

Vaccine

Volumn 32, Issue 8, 2014, Pages 904-908

  Mahoney, Richard ^a  

^a Global Health Consultant   (United States)

Author keywords

Dengue; Introduction; Prelicensure; Vaccines

Indexed keywords

DENGUE VACCINE;

DENGUE; DEVELOPING COUNTRY; HUMAN; LICENSING; NONHUMAN; ORGANIZATION AND MANAGEMENT; PRIORITY JOURNAL; REVIEW;

DENGUE; INTRODUCTION; PRELICENSURE; VACCINES;

DENGUE; DENGUE VACCINES; DEVELOPING COUNTRIES; HEALTH POLICY; IMMUNIZATION PROGRAMS; LICENSURE; PUBLIC SECTOR;

EID: 84893658459     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.12.061     Document Type: Review

References (12)

1. Mahoney R., Maynard J.E. The introduction of new vaccines into developing countries. Vaccine 1999, 17(7-8):646-652.
2. Mahoney R., Ramachandran S., Xu Z.Y. The introduction of new vaccines into developing countries. II. Vaccine financing. Vaccine 2000, 18(24):2625-2635.
3. Mahoney R.T., Pablos-Mendez A., Ramachandran S. The introduction of new vaccines into developing countries. III. The role of intellectual property. Vaccine 2004, 22:786-792.
4. Mahoney R.T., Krattiger A., Clemens J.D., Curtiss R. The introduction of new vaccines into developing countries. IV. Global access strategies. Vaccine 2007, 25(20):4003-4011.
5. Levine O.S., Hajjeh R., Wecker J., Cherian T., O'Brien K.L., Knoll M., et al. A policy framework for accelerating adoption of new vaccines. Human Vaccines 2010, 6(12):1021-1024.
6. Brooks A., Smth T.A., de Savigny D., Lengeler C. Implementing new health interventions in developing countries: why do we lose a decade or moreα. BMC Public Health 2012, 12(683):17.
7. Dengue and dengue hemorrhagic fever 1997, CABI Publishing, Eastbourne, UK. D.J. Gubler, G. Kuno (Eds.).
8. Brady O.J., Gething P.W., Bhatt S., Messina J.P., Brownstein J.S., Hoen A.G., et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Neglected Tropical Diseases 2012, 6(8):e1760.
9. Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., et al. The global distribution and burden of dengue. Nature 2013, 496(7446):504-507.
10. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. The Lancet 2012, 380(9853):1559-1567.
11. Murphy B.R., Whitehead S.S. Immune response to dengue virus and prospects for a vaccine. Annual Review of Immunology 2011, 29:587-619.
12. Davis M.M., Butchart A.T., Wheeler J.R., Coleman M.S., Singer D.C., Freed G.L. Failure-to-success ratios: transition probabilities and phase lengths for prophylactic vaccines versus other pharmaceuticals in the development pipeline. Vaccine 2011, 29(51):9414-9416.